Previous 10 | Next 10 |
2023-10-26 10:50:51 ET More on Xencor Xencor: A Mid-Stage Clinical Company With Falling Losses Vir Biotech nabs $50M BARDA funding to discover antibody therapies Seeking Alpha’s Quant Rating on Xencor For further details see: Xencor finance chief t...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that John J. Kuch, senior vice president and chief financial officer, plans to retire in March 2024, after a 23-year...
2023-10-20 23:02:01 ET Summary Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hematologic cancers and blood disorders. Xencor's p...
2023-10-03 09:50:40 ET More on Vir, Xencor, etc. Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity Vir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript ...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of ...
2023-08-06 03:20:23 ET Xencor, Inc. (XNCR) Q2 2023 Earnings Conference Call August 3, 2023, 04:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer ...
2023-08-03 16:32:45 ET Xencor press release ( NASDAQ: XNCR ): Q2 GAAP EPS of -$0.37 beats by $0.43 . Revenue of $45.5M (+50.8% Y/Y) beats by $19.22M . Cash, cash equivalents, receivables and marketable debt securities totaled $531.4 million as of June 30, 2023,...
-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the ...
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2023 financial results after the market closes on Thursday, August 3, 2023. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...
2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...